Technology Offerings

Transitional cell carcinoma (TCC) of the urinary bladder is the most common genitourinary cancer. Diagnosis of TCC currently relies on cystoscopy and urine cytology. Both examination methods have limitations. The present technology describes a novel urinary marker for the detection of bladder cancer. With a sensitivity of 85 % and a specificity of 86.4 % the potential marker exceeds currently commercially available bladder cancer associated marker proteins.

The field of application is under water welding (e.g. offshore platforms or inland water-ways) using electric arc welding including continuous filler wire supply. In comparison to the state of the art, the new welding system allows a creation of endless an slag-free welding seam in hyper-baric wet areas by the hand of the diver.

To date, the diagnosis of the severe infectious disease leishmaniosis is still highly unreliable in endemic areas of Eastern Africa, since the pathogen occurring in these regions differs from pathogens present in other endemic areas of South Africa and Asia. Moreover, leishmaniasis is also spreading in southern Europe because infected dogs represent a major source of risk for the transmission to humans.

A cost-effective and time-efficient diagnostics was developed which provides a more
reliable diagnosis of leishmaniasis in humans and animals as compared to currently
available diagnostics. This diagnostics is particularly suitable for a use as rapid test,
allowing an uncomplicated application outside of clinics and laboratories and
consequently a more efficient and improved diagnosis of leishmaniasis in hospitals
and in the field.

Several pathological conditions as autoimmune and inflammatory diseases are due to an excessive T cell activity. Treatment modalities are based on the relief from symptoms, whereby immune suppressive biologicals are rapidly expanding, owing to the good efficacy and safety profiles. However, for the regulation of the starting point of the disease-causing processes no agents exist until now. For that we offer a new agent with an exceptional stringent and specific suppression of T cell activation, whereby the inactivation is reversible. With this invention it is not only possible to address T cells in their entirety, but also antigen-specific T cells. Membrane mobility characteristics have not to be considered, because the target is located on the outside of T cells.

Peripheral artery occlusive disease (PAOD) ranks among the most frequent chronic diseases worldwide. Common therapies comprise mechanical interventions, which are not suitable for a considerable number of patients. We offer a new pharmaceutical, achieving an almost healthy blood flow due to an increased growth of collateral vessels. For that immune cells of the patient are used, giving reason to expect a good tolerance and thereby avoiding rejection reactions and the transmission of pathogens.

Graft versus Host Disease (GVHD) is one of the major complications associated with transplantation. It is caused by donor T cells, which recognize the genetically dissimilar recipient and therefore attack the host’s body cells. At present there is no effective therapy available. We offer a simple method, whereby the transplant once is treated ex vivo with a well known substance prior to transplantation. For that only a very low concentration of the substance and a short incubation time are used. Remarkably, GVHD is reduced significantly. Due to the ex vivo treatment no side effects are expected.